Carri Livingston
Payments from drug & device makers
Across 139 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$427
- Novo Nordisk$309
- Lilly USA, LLC$226
- Takeda Pharmaceuticals U.S.A., Inc.$197
- Bayer$190
- Boehringer Ingelheim$187
- plus $607 from 10 others
What the payments were for
- Food & beverage$2,143100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $427 |
| Novo Nordisk | 19 | $309 |
| Lilly USA, LLC | 16 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $197 |
| Bayer | 11 | $190 |
| Boehringer Ingelheim | 11 | $187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $166 |
| AstraZeneca | 8 | $141 |
| Pfizer | 7 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $82 |
| Shield Therapeutics Inc | 1 | $22 |
| Tolmar, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Amgen | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,143 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $35,807 |
| JardianceEmpagliflozin | 17 | $23,024 |
| FarxigaDapagliflozin Propanediol | 15 | $19,840 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $18,820 |
| Gabapentin | 46 | $665 |
| Diclofenac Sodium | 17 | $588 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $497 |
| Rosuvastatin Calcium | 66 | $491 |
| Montelukast Sodium | 23 | $432 |
| Levocetirizine Dihydrochloride | 25 | $410 |
| Omeprazole | 17 | $395 |
| Levothyroxine Sodium | 55 | $371 |
| Fluticasone Propionate | 34 | $336 |
| Trazodone Hcl | 28 | $326 |
| Buspirone Hcl | 16 | $324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $309 | $35,80734 claims |
| Boehringer IngelheimJardiance | $187 | $23,02417 claims |
| AstraZenecaFarxiga | $141 | $19,84015 claims |
| GSKTrelegy Ellipta | $18 | $18,82025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Byron
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.